D.E. Shaw & Co’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

D.E. Shaw & Co’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-121,286	Closed	-$3.26M	–	5991
2022 Q1	$3.26M	Buy	121,286 +17,130	+16%	+$576K	﹤0.01%	2796
2021 Q4	$4.97M	Sell	104,156 -5,262	-5%	-$235K	﹤0.01%	2389
2021 Q3	$7.27M	Sell	109,418 -19,601	-15%	-$1.4M	0.01%	1779
2021 Q2	$10.1M	Sell	129,019 -126,910	-50%	-$9.38M	0.01%	1488
2021 Q1	$24.2M	Buy	255,929 +161,628	+171%	+$19.2M	0.02%	834
2020 Q4	$11.5M	Buy	+94,301	New	+$10.3M	0.01%	1303
2020 Q3	–	Sell	-3,576	Closed	-$231K	–	4293
2020 Q2	$231K	Buy	+3,576	New	+$206K	﹤0.01%	3728
2020 Q1	–	Sell	-4,241	Closed	-$264K	–	4388
2019 Q4	$264K	Buy	+4,241	New	+$202K	﹤0.01%	3692

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

D.E. Shaw & Co's TPTX Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 121,286 shares — an estimated $3.26M sold.

D.E. Shaw & Co first reported a position in TPTX in Q4 2019 and held it in 8 quarters. The position peaked at $24.2M in Q1 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

D.E. Shaw & Co reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
D.E. Shaw & Co sold 121,286 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $3.26M.
D.E. Shaw & Co first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 8 quarters.
D.E. Shaw & Co's Turning Point Therapeutics, Inc. Common Stock position peaked at $24.2M in Q1 2021.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.